Literature DB >> 14534919

Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease.

Yoshikuni Mizuno1, Nobuo Yanagisawa, Sadako Kuno, Mitsutoshi Yamamoto, Kazuko Hasegawa, Hideki Origasa, Hisayuki Kowa.   

Abstract

We compared the efficacy and safety of pramipexole (PPX) with placebo in the treatment of advanced Parkinson's disease (PD) as an adjunct to levodopa. A bromocriptine (BR) group was included to enable determination of the noninferiority of PPX relative to BR as the standard treatment. Copyright 2003 Movement Disorder Society

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14534919     DOI： 10.1002/mds.10508

Source DB:  PubMed          Journal:  Mov Disord        ISSN： 0885-3185            Impact factor:   10.338


  14 in total

Review 1.  Parkinson's disease.

Authors:  Carl E Clarke; A Peter Moore
Journal:  BMJ Clin Evid       Date:  2007-08-01

2.  Adverse effects produced by different drugs used in the treatment of Parkinson's disease: A mixed treatment comparison.

Authors:  Bao-Dong Li; Zhen-Yun Bi; Jing-Feng Liu; Wei-Jun Si; Qian-Qian Shi; Li-Peng Xue; Jing Bai
Journal:  CNS Neurosci Ther       Date:  2017-09-04       Impact factor: 5.243

Review 3.  Role of pramipexole in the management of Parkinson's disease.

Authors:  Angelo Antonini; Paolo Barone; Roberto Ceravolo; Giovanni Fabbrini; Michele Tinazzi; Giovanni Abbruzzese
Journal:  CNS Drugs       Date:  2010-10       Impact factor: 5.749

Review 4.  Dopamine receptor agonists for the treatment of early or advanced Parkinson's disease.

Authors:  Santiago Perez-Lloret; Olivier Rascol
Journal:  CNS Drugs       Date:  2010-11       Impact factor: 5.749

Review 5.  Risk of valvular heart disease associated with the use of dopamine agonists in Parkinson's disease: a systematic review.

Authors:  Malcolm Steiger; W Jost; F Grandas; G Van Camp
Journal:  J Neural Transm (Vienna)       Date:  2009-01-14       Impact factor: 3.575

Review 6.  Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease: meta-analysis of randomized controlled trials.

Authors:  Jaime Kulisevsky; Javier Pagonabarraga
Journal:  Drug Saf       Date:  2010-02-01       Impact factor: 5.606

7.  Discontinuation of ropinirole and pramipexole in patients with Parkinson's disease: clinical practice versus clinical trials.

Authors:  Maurits E L Arbouw; Kris L L Movig; Henk-Jan Guchelaar; Petra J E Poels; Jeroen P P van Vugt; Cees Neef; Toine C G Egberts
Journal:  Eur J Clin Pharmacol       Date:  2008-07-15       Impact factor: 2.953

Review 8.  Impact of newer pharmacological treatments on quality of life in patients with Parkinson's disease.

Authors:  David A Gallagher; Anette Schrag
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

9.  Once-daily pramipexole for the treatment of early and advanced idiopathic Parkinson's disease: implications for patients.

Authors:  Angelo Antonini; Daniela Calandrella
Journal:  Neuropsychiatr Dis Treat       Date:  2011-05-15       Impact factor: 2.570

10.  Dyskinesias and treatment with pramipexole in patients with Parkinson's disease.

Authors:  John C P Piedad; Andrea E Cavanna
Journal:  Parkinsons Dis       Date:  2012-02-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.